EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines - BioNTech (NASDA

European Medical Agency (EMA) has approved additional manufacturing sites for mRNA-based coronavirus vaccines developed by Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) to help boost production amid an increase in infections.
Related: Pfizer's CEO Says Work In Progress For Specialized Vaccine Targeting COVID-19 Delta Variant.
The agency's human medicines committee approved a site at Saint Remy Sur Avre in France for the Pfizer-BioNTech vaccine, Comirnaty.
The Delpharm-operated site will help provide up to 51 million additional doses of Comirnaty in 2021.
The EMA also approved a new manufacturing line at BioNTech's site at Marburg in Germany, which would help boost capacity for the vaccine's active substance by about 410 million doses this year.
The EMA also approved an additional site at Bloomington, Indiana, for Moderna's vaccine, Spikevax, and several other locations involved in testing and packaging.
The Bloomington site is operated by Catalent Inc (NYSE:CTLT).
The recommendations do not require a decision by the European Commission, and the sites can become operational immediately.
Also See: Isreal Study Shows Pfizer Booster Shot Slowing Spread of Delta Variant In Elderly.
Related content: Benzinga's Full FDA Calendar.
Price Action: PFE shares are down 0.41% at $48.36, BNTX stock is down 1.18% at $363.85, and MRNA is down 1.67% at $388.33 during the premarket session on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.